Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021
Relmada Therapeutics, Inc. (Nasdaq: RLMD) will release its financial results for Q1 2021 after market close on May 12, 2021. A corporate update conference call and audio webcast are scheduled for 4:30 PM ET on the same day. The company focuses on developing treatments for central nervous system diseases, particularly major depressive disorder, with its lead program, REL-1017, currently in late-stage development.
- The lead program, REL-1017, is advancing to late-stage development for major depressive disorder.
- Upcoming financial results may provide insights into the company's progress and performance.
- None.
NEW YORK, May 6, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2021 after the market close on Wednesday, May 12, 2021. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Wednesday, May 12, 2021.
Live Conference Call & Webcast: | |
Toll Free: | 877-407-0792 |
International: | 201-689-8263 |
Conference ID: | 13719413 |
Webcast: | |
A replay of the webcast will be available on the Investors section of the company's website.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
Tim@LifeSciAdvisors.com
Media Inquiries:
FischTank PR
Relmada@FischTankPR.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-report-first-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-may-12-2021-301286161.html
SOURCE Relmada Therapeutics, Inc.
FAQ
When will Relmada Therapeutics report its Q1 2021 financial results?
What is REL-1017 and its significance for Relmada Therapeutics?
What time is the Relmada Therapeutics conference call on May 12, 2021?
